ea0032p561 | Endocrine tumours and neoplasia | ECE2013
Iacovazzo Donato
, Lugli Francesca
, Plastino Francesca
, Schinzari Giovanni
, Bianchi Antonio
, Fusco Alessandra
, Rindi Guido
, Pontecorvi Alfredo
, De Marinis Laura
, Barone Carlo Antonio Mario
Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...